OMERACT review narrows systemic lupus outcome selection to 25 candidate domains
A broad scoping review has pared the sprawling literature on systemic lupus erythematosus outcomes into a more workable framework for consensus building. Investigators screened clinical trials and systematic reviews published since 2010, then extracted outcome domains that appeared relevant to the disease burden of SLE. From 4,063 records identified across five databases, 507 studies met inclusion criteria and advanced to data extraction. After winnowing and binning by the OMERACT SLE Advisory Group, the field contracted to 25 candidate domains.
The result is not a final core outcome set, but it is a decisive narrowing of the field.
For a disease as protean as lupus, that narrowing matters because outcome measurement has long been fragmented across organ systems, symptom clusters, and treatment goals. SLE can injure the skin, joints, kidneys, blood, nervous system, and constitutional status in ways that do not move in lockstep. A trial that tracks only one dimension risks missing meaningful benefit or harm elsewhere. A core outcome set is meant to impose discipline on that chaos by forcing future studies to measure the same essential domains in a consistent way.
Five databases, one question: which lupus domains deserve to be measured?
The review set out to identify candidate SLE domains from the published literature for consideration in the development of a core outcome set. That design places the exercise squarely in the pre-consensus phase, where breadth matters more than parsimony. The investigators searched five databases and focused on clinical trials and systematic reviews published since 2010, a window that captures modern therapeutic development and a large body of evolving outcome measurement.
From the 4,063 studies initially identified, 507 passed eligibility screening. That is a substantial pruning process in its own right, and it reflects the heterogeneity of lupus research. Studies in this space often differ by organ involvement, intervention type, follow-up duration, and the outcomes they privilege. The scoping review did not attempt to rank these domains by importance at the bedside. Instead, it assembled the raw material needed to decide which outcome measures are indispensable across future SLE research.
Once extracted, the candidate domains and items were winnowed and binned by the OMERACT SLE Advisory Group. The final output was 25 candidate domains, a number the investigators judged feasible and manageable for movement into the core domain consensus stage.
Why a smaller domain set can improve lupus trials
Lupus trial design has always struggled with a tension between comprehensiveness and practicality. Too few outcomes and the study can fail to capture the breadth of disease impact. Too many, and the measurement burden becomes unwieldy, especially when patients are already dealing with fatigue, pain, organ-threatening disease, and complex immunosuppressive regimens. A core outcome set is intended to reduce that burden while preserving what matters most.
The 25 domains were described as covering the important aspects of SLE and the four core areas of disease impact according to the OMERACT framework. That framework is central here because it provides the structure for deciding whether an outcome belongs in the core set. In a disease with variable manifestations, a standardized outcome architecture helps prevent selective reporting and reduces the risk that trial results look favorable simply because the wrong outcomes were chosen.
A concise domain set also makes cross-trial comparison more credible. When studies assess different endpoints with different definitions, meta-analysis becomes a fragile exercise. When they measure the same core outcomes, treatment effects become easier to compare, pool, and interpret. For a condition such as SLE, where therapeutic decisions often hinge on modest but meaningful differences in flare control, organ protection, and tolerability, that standardization can alter the interpretability of the literature itself.
Patient input still sits ahead of the consensus stage
The current 25-domain list is not the final word. The investigators will supplement the candidate domains with ongoing qualitative research with patients living with SLE before proceeding to the consensus stage. That step is essential because lupus outcomes are not defined solely by laboratory abnormalities or physician-observed disease activity. Fatigue, pain, functional limitation, cognitive symptoms, and the daily burden of treatment can shape the lived experience of SLE in ways that traditional trial endpoints may underrepresent.
A domain set built only from published trials and systematic reviews could still miss patient-valued effects that have not been consistently studied or reported. Qualitative work provides a corrective, allowing the eventual consensus process to incorporate the language and priorities of people living with the disease rather than relying only on the research record. In a multisystem illness where symptom burden and organ injury can diverge, that patient perspective is not decorative. It is necessary to define what a meaningful treatment effect actually looks like.
The practical value of this review lies in its restraint. Instead of trying to force every measurable lupus feature into a single endpoint list, the OMERACT process has identified a candidate set large enough to reflect disease complexity but small enough to be used in future consensus work. That balance is difficult to strike in SLE, where heterogeneity has long diluted clinical trial comparability. A 25-domain framework does not solve that problem on its own, but it creates a credible path toward consistency.
A workable bridge from literature review to lupus consensus
The most consequential detail in this review is the transition from 4,063 identified studies to 25 candidate domains. That compression is a signal that the literature can be distilled into a domain structure that investigators and methodologists can actually use. It also suggests that the field may finally be moving toward a more stable vocabulary for SLE outcomes, one that can support future trial design without flattening the complexity of the disease.
The next step will determine whether those 25 domains survive patient review and consensus testing. Until that happens, the list remains provisional, and the final composition of the SLE core outcome set is still open to change. The review itself does not settle which domains belong in every trial; it defines the field from which that judgment will be made.